Described are implantable devices having reservoirs for the sustained release of therapeutic agents. The devices are configured to be at least partially implanted in an eye and include a retention structure and a penetrable element coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element is positioned in fluid communication with an outlet of the device and a reservoir having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.

An apparatus for delivering therapeutic agent to an eye comprises a body, a cannula, a hollow needle, and an actuation assembly. The cannula extends distally from the body and is sized and configured to be insertable between a choroid and a sclera of a patient's eye. The actuation assembly is operable to actuate the needle relative to the cannula to thereby drive a distal portion of the needle along an exit axis that is obliquely oriented relative to the longitudinal axis of the cannula. The cannula may be inserted through a sclerotomy incision to position a distal end of the cannula at a posterior region of the eye, between the choroid and sclera. The needle may be advanced through the choroid to deliver the therapeutic agent adjacent to the potential space between the neurosensory retina and the retinal pigment epithelium layer, adjacent to the area of geographic atrophy.

An ophthalmic implant including an intraocular lens (IOL) and at least one drug delivery device. The IOL including an anterior side, a posterior side, a lens, and at least one haptic extending outwardly from the lens and including a first haptic extending from the lens at a first optic-haptic junction. The at least one drug delivery device including a first drug delivery device including a pad and a fixation portion extending from the pad. The pad including at least one therapeutic agent contained therein, an anterior surface, a posterior surface, and a sidewall extending around the pad and between the anterior surface and the posterior surface. The drug delivery device configured for attachment to the IOL via the fixation portion. In an assembled state of the implant, the first drug delivery device is attached to the IOL and the pad overlays the first optic-haptic junction.

A system for treating an eye of a patient in need including a delivery device having a housing sized to be held by an operator, an actuator and a distal nose cone; a needle coupled to and extending distal from the nose cone, the needle having a lumen and a beveled distal end defining a distal opening having a sharpened tip and heel proximal the distal opening; and a retention plug positioned within and spanning the lumen of the needle proximal to the heel; and an intraocular implant positioned within the lumen of the needle proximal to the retention plug. The retention plug is formed from a flowable retainer solution of hydroxypropyl methylcellulose (HPMC) in water having a concentration that is greater than 2.5% w:w and less than about 4% w:w. Related devices and methods are provided.

A medicine administration tool configured for use in a transocular iontophoresis device for forming an electric circuit between a first electrode and a second electrode and supplying medicine to an eyeball, includes: a tubular member having a first lower end configured to face the eyeball; an inner member having a second lower end configured to face the eyeball, the inner member being accommodated in a space of the tubular member and forming a medicine accommodating chamber for accommodating the medicine between the inner member and the tubular member; and a support member movably supporting the inner member with respect to the tubular member.

A method of delivering a pharmaceutical composition to Schlemm’s canal of an eye is disclosed. The method may comprise inserting a drug delivery device in conjunction with a microstent into Schlemm’s canal. The drug delivery device may comprise a bioerodable polymer and a pharmaceutical composition, and the drug delivery device may be configured to erode over time and to elute the pharmaceutical composition into aqueous humor within Schlemm’s canal as it erodes.

An ablatable corneal inlay for correction of refractive errors and/or presbyopia, and a method of correcting refractive errors and presbyopia in an eye of a patient using an ablatable corneal inlay is disclosed herein.

Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

Delivery devices, systems and methods are provided for inserting an implant into an eye. The delivery or inserter devices or systems can be used to dispose or implant an ocular stent or implant, such as a shunt, in communication with a suprachoroidal space of the eye. The implant can drain fluid from an anterior chamber of the eye to a physiologic outflow path of the eye, such as, the suprachoroidal space or other portion of the uveoscleral outflow path. The delivery or inserter devices or systems can be used in conjunction with other ocular surgery, for example, but not limited to, cataract surgery through a preformed corneal incision, or independently with the inserter configured to make a corneal incision. The implant can be preloaded with or within the inserter to advantageously provide a sterile, easy-to-use package for use by an operator.

A microfluidic flow restrictor that uses micron-sized beads to impede flow is described. The flow rate can be adjusted by adding or removing the beads using injection needles through self-sealing ports, one injection needle injecting or aspirating beads and another injection needle pushing or pulling fluid from outside of a bead trap within the flow restrictor. In alternative embodiments, the beads or other filler material can be trapped in a manifold bead trap such that they block a subset of fluid channels of the flow restrictor, allowing fluid to flow freely through the rest of the fluid channels. The flow restrictor can be integrated with a contact lens or implantable medical device for use in dispensing liquid therapeutic agents at flow rates of microliters per minute or moving body fluids at a controlled rate from one part of the body to another.